
Breaking News: Relmada Therapeutics’ Phase 3 Trial Deemed Futile by Data Monitoring Committee – What This Means for the Future of Treatment
Relmada Therapeutics, Inc. announces update on REL-1017 program Reliance II Phase 3 Study Results The DMC conducted an interim analysis on the Reliance II Phase 3 study of REL-1017, a drug developed by Relmada Therapeutics, Inc. Unfortunately, the analysis indicated that the study is futile and is unlikely to meet the primary efficacy endpoint with…